01.04.21
Ingredients supplier Sabinsa recently announced that it has been awarded five new patents on a number of its flagship ingredients, capping off a year in which the company achieved several other awards and certifications.
Two patents were awarded to the company for its probiotic lactobacillus ingredient, LactoSpore. The first patent (US10792295) covered LactoSpore’s usage in combination with B-glucogallin, due to its inhibitory effect on the growth of Helicobacter pylori, an infectious bacteria associated with gastric distress. The combination can be used to manage or prevent complications due to Helicobacter pylori infections, including extra-gastroduodenal disorders, the company said. The ingredient is approved by the patent for use in tablets, capsules, gummies, syrups, powders, suspensions, emulsions, chewables, and candies. Sabinsa also received a patent (US10806760) for LactoSpore which was granted for its potential in reducing intestinal gas (flatulence) formed due to microbial food fermentation. In addition to a direct mechanism of action, the patent claims a method for inhibiting the growth of gas-producing microbes including E. coli, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter johnsonii, Methanobrevibacter smithii, Bilophila wadsworthia, and Clostridium difficile.
Sabinsa also has a new patent in the sports nutrition category (US10716823) for an extract comprising boswellic acids and polysaccharides extracted from Boswellia serrata called Boswellin PS. The patent covers the ingredient for use in combination with either the concentrate of the liquid endosperm of Cocos nucifera, or the extract of Emblica officinalis fruit standardized to contain at least 10% B-glucogallin. This composition was evidenced to increase the endurance capacity under sustained physical activity, and has also been suggested in clinical research to exhibit a protective effect against hypoxic injury, modify biochemical parameters, and increase neuromuscular coordination in subjects exposed to amplified physical stress.
Another of Sabinsa’s ingredients, containing a combination of extracts from Allium sativum, Beta vulgaris, Nigella sativa, and Terminalia arjuna, standardized to contain specific active metabolites, received a patent for its ability to inhibit the protein Prostaglandin Transporter (PGT). PGT is becoming a target by pharmaceutical developers due to the possible role of PGs in the cells as a precursor to conditions including hypertension and other cardiovascular complications.
Finally, Sabinsa also received a patent (US10864242) for a composition formulated to manage male sexual dysfunction. A clinical trial found that a composition containing Withania somnifera, Mucuna pruriens, Coleus forskohlii, and Kaempferia parviflora extracts, along with Sabinsa’s proprietary piperine extract for bioavailability, was effective in reducing a number of conditions related to male sexual dysfunction. These conditions included erectile dysfunction, premature ejaculation, delayed or inhibited ejaculation, and reduced libido, and there were a number of biochemical markers and pathways to which this benefit was attributed, the company said.
“Patenting our discoveries is an important part of protecting the investments our customers make when they formulate with our ingredients,” Sabinsa founder and chairman Dr. Muhammed Majeed, said. “Innovation drives the industry, and more importantly provides additional ways to contribute to the health of humanity.”
The awards Sabinsa received this year included a lifetime achievement award to Dr. Majeed for “excellence in the field of biology and research on Ayurvedic products,” awarded on Dec. 13 by the Indian Association for the Study of Traditional Asian Medicine. Additionally, Sabinsa’s parent company, Sami-Sabinsa Group, received an award for the Best Patent Portfolio in Life Science/Pharma, and Best Trademark Portfolio in Life Science/Pharma during the 6th annual CII (Confederation of Indian Industry) Industrial Intellectual Property Awards.
Two patents were awarded to the company for its probiotic lactobacillus ingredient, LactoSpore. The first patent (US10792295) covered LactoSpore’s usage in combination with B-glucogallin, due to its inhibitory effect on the growth of Helicobacter pylori, an infectious bacteria associated with gastric distress. The combination can be used to manage or prevent complications due to Helicobacter pylori infections, including extra-gastroduodenal disorders, the company said. The ingredient is approved by the patent for use in tablets, capsules, gummies, syrups, powders, suspensions, emulsions, chewables, and candies. Sabinsa also received a patent (US10806760) for LactoSpore which was granted for its potential in reducing intestinal gas (flatulence) formed due to microbial food fermentation. In addition to a direct mechanism of action, the patent claims a method for inhibiting the growth of gas-producing microbes including E. coli, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter johnsonii, Methanobrevibacter smithii, Bilophila wadsworthia, and Clostridium difficile.
Sabinsa also has a new patent in the sports nutrition category (US10716823) for an extract comprising boswellic acids and polysaccharides extracted from Boswellia serrata called Boswellin PS. The patent covers the ingredient for use in combination with either the concentrate of the liquid endosperm of Cocos nucifera, or the extract of Emblica officinalis fruit standardized to contain at least 10% B-glucogallin. This composition was evidenced to increase the endurance capacity under sustained physical activity, and has also been suggested in clinical research to exhibit a protective effect against hypoxic injury, modify biochemical parameters, and increase neuromuscular coordination in subjects exposed to amplified physical stress.
Another of Sabinsa’s ingredients, containing a combination of extracts from Allium sativum, Beta vulgaris, Nigella sativa, and Terminalia arjuna, standardized to contain specific active metabolites, received a patent for its ability to inhibit the protein Prostaglandin Transporter (PGT). PGT is becoming a target by pharmaceutical developers due to the possible role of PGs in the cells as a precursor to conditions including hypertension and other cardiovascular complications.
Finally, Sabinsa also received a patent (US10864242) for a composition formulated to manage male sexual dysfunction. A clinical trial found that a composition containing Withania somnifera, Mucuna pruriens, Coleus forskohlii, and Kaempferia parviflora extracts, along with Sabinsa’s proprietary piperine extract for bioavailability, was effective in reducing a number of conditions related to male sexual dysfunction. These conditions included erectile dysfunction, premature ejaculation, delayed or inhibited ejaculation, and reduced libido, and there were a number of biochemical markers and pathways to which this benefit was attributed, the company said.
“Patenting our discoveries is an important part of protecting the investments our customers make when they formulate with our ingredients,” Sabinsa founder and chairman Dr. Muhammed Majeed, said. “Innovation drives the industry, and more importantly provides additional ways to contribute to the health of humanity.”
The awards Sabinsa received this year included a lifetime achievement award to Dr. Majeed for “excellence in the field of biology and research on Ayurvedic products,” awarded on Dec. 13 by the Indian Association for the Study of Traditional Asian Medicine. Additionally, Sabinsa’s parent company, Sami-Sabinsa Group, received an award for the Best Patent Portfolio in Life Science/Pharma, and Best Trademark Portfolio in Life Science/Pharma during the 6th annual CII (Confederation of Indian Industry) Industrial Intellectual Property Awards.
